[go: up one dir, main page]

ATE399323T1 - Verfahren zur bestimmung von amyloidogenen proteinen - Google Patents

Verfahren zur bestimmung von amyloidogenen proteinen

Info

Publication number
ATE399323T1
ATE399323T1 AT00980905T AT00980905T ATE399323T1 AT E399323 T1 ATE399323 T1 AT E399323T1 AT 00980905 T AT00980905 T AT 00980905T AT 00980905 T AT00980905 T AT 00980905T AT E399323 T1 ATE399323 T1 AT E399323T1
Authority
AT
Austria
Prior art keywords
aggregation
assay
determining
amyloid
peptide
Prior art date
Application number
AT00980905T
Other languages
English (en)
Inventor
Girija Krishnamurthy
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE399323T1 publication Critical patent/ATE399323T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
AT00980905T 1999-12-29 2000-12-01 Verfahren zur bestimmung von amyloidogenen proteinen ATE399323T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/474,970 US6399314B1 (en) 1999-12-29 1999-12-29 Methods of detection of amyloidogenic proteins

Publications (1)

Publication Number Publication Date
ATE399323T1 true ATE399323T1 (de) 2008-07-15

Family

ID=23885720

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00980905T ATE399323T1 (de) 1999-12-29 2000-12-01 Verfahren zur bestimmung von amyloidogenen proteinen

Country Status (21)

Country Link
US (1) US6399314B1 (de)
EP (1) EP1242822B1 (de)
JP (1) JP2003519383A (de)
KR (1) KR20020070470A (de)
CN (1) CN1211661C (de)
AT (1) ATE399323T1 (de)
AU (1) AU774377B2 (de)
BR (1) BR0016883A (de)
CA (1) CA2395789C (de)
DE (1) DE60039310D1 (de)
DK (1) DK1242822T3 (de)
EA (1) EA005582B1 (de)
ES (1) ES2309003T3 (de)
HK (1) HK1046550B (de)
IL (2) IL150080A0 (de)
MX (1) MXPA02006362A (de)
NO (1) NO20023163L (de)
NZ (1) NZ519612A (de)
PL (1) PL356813A1 (de)
PT (1) PT1242822E (de)
WO (1) WO2001050134A2 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
DE19923811C1 (de) * 1999-05-20 2000-12-07 Robert Koch Inst Verfahren zur Diagnose TSE-induzierter Veränderungen in Geweben mittels Infrarotspektroskopie
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6689753B1 (en) * 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
EP2151187A1 (de) 2000-08-21 2010-02-10 The General Hospital Corporation Verfahren zur Diagnose eines neurodegenerativen Leidens
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
EP2298361A3 (de) * 2001-04-27 2011-05-04 The General Hospital Corporation Okulare Diagnose der Alzheimer-Krankheit
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
EP1395833B1 (de) * 2001-05-31 2013-02-27 Adlyfe, Inc. Verfahren zum erkennen von inkorrekt gefalteten proteinen
US20060057107A1 (en) * 2001-12-21 2006-03-16 Shaked Ze Ev Combination treatment for multiple sclerosis
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1380290A1 (de) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-Beta-Strukturweg und seine therapeutische Relevanz
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US20050048539A1 (en) * 2003-06-13 2005-03-03 The General Hospital Corporation Methods to monitor molecule conformation and molecule/molecule proximity
SE0401219D0 (sv) * 2004-05-10 2004-05-10 Biochromix Ab Metoder för detektera konformationsförändringar eller aggregering hos proteiner med hjälp av konjugerade polyelektrolyter
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
US20060257396A1 (en) * 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
ES2434732T3 (es) 2004-12-15 2013-12-17 Janssen Alzheimer Immunotherapy Anticuerpos para beta-amiloide humanizados para su uso en mejorar la cognición
ES2396555T3 (es) * 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
JP4568840B2 (ja) * 2004-12-28 2010-10-27 国立大学法人金沢大学 アルツハイマー病の検査方法
WO2006069697A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Colorimetrically assessing peptide characteristics
AU2006214463B2 (en) * 2005-02-15 2012-08-30 Presympto, Inc. Method for detecting misfolded proteins and prions
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
EP2386861A3 (de) * 2005-07-13 2012-07-18 Crossbeta Biosciences B.V. Cross-Beta-Struktur-bindende Verbindungen
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
BRPI0613525A2 (pt) * 2005-07-13 2011-05-31 Crossbeta Biosciences Bv métodos para produzir uma composição imunogênica, para melhorar a imunogenicidade de uma composição, para intensificar a imunogenicidade de uma composição de vacina, e para determinar a quantidade de estruturas beta-cruzadas em uma composição de vacina, usos de estruturas beta-cruzadas, e de uma composição imunogênica, vacina de subunidade, e, composição imunogênica
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
AU2007277186B2 (en) * 2006-07-28 2014-01-30 Presympto, Inc. Peptide probes for diagnostics and therapeutics
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2058000A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung
EP2058001A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Steigerung der Immunogenizität von Antigenen
US20100021390A1 (en) * 2008-03-17 2010-01-28 The Research Foundation Of State University Of New York Fluorescent Analogs Of The Islet Amyloid Polypeptide
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
RU2509155C1 (ru) * 2012-10-25 2014-03-10 Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
GB201303507D0 (en) * 2013-02-27 2013-04-10 Hollfelder Florian Assays
US9588129B2 (en) * 2013-03-15 2017-03-07 Amira Medical Technologies Inc. Methods for analyzing blood to detect diseases associated with abnormal protein aggregation
CN104803993B (zh) * 2015-03-01 2017-11-03 四川大学 一种具有Aβ亲和力的荧光化合物及其用途
CN105651752B (zh) * 2016-02-26 2019-04-12 国家纳米科学中心 淀粉样蛋白的检测方法
CN105717182B (zh) * 2016-03-10 2018-05-11 中南大学 一种用于同步检测淀粉样多肽单体和聚集体的生物传感器及其构建方法和应用
WO2018136910A1 (en) * 2017-01-23 2018-07-26 Rensselaer Polytechnic Institute Systems and methods for binding amyloid fibrils using fluorescent protein
CN108489941B (zh) * 2018-01-31 2021-07-27 吉林大学 溴酚蓝在作为检测牛胰岛素淀粉样纤维探针和作为牛胰岛素淀粉样纤维抑制剂方面的应用
US20210165001A1 (en) * 2018-08-03 2021-06-03 The University Of Hong Kong Compositions and methods for detection and imaging of amyloid fibrils, amyloid plaques, rna, and nucleoli
CA3120066A1 (en) 2018-11-14 2020-05-22 University Of Kentucky Research Foundation Diagnosis of diabetes by detecting aggregated amylin in erythrocytes
CN111504957B (zh) * 2019-01-31 2021-12-03 吉林大学 一种维多利亚蓝b及其衍生物在制备异构化蛋白的探针或抑制剂中的应用
KR102258048B1 (ko) * 2019-05-30 2021-05-31 주식회사 캔티스 아밀로이드 베타 올리고머의 검출 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2013396A1 (en) * 1989-04-05 1990-10-05 Dennis J. Selkoe Diagnostic method for alzheimer's disease: examination of non-neural tissue
US5276059A (en) 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
CA2242851A1 (en) 1995-08-17 1997-02-27 The Ontario Cancer Institute Protein fibril assembly assay
JPH0995444A (ja) * 1995-10-02 1997-04-08 Teijin Ltd アミロイド蛋白凝集阻害剤
EP1003539A4 (de) 1997-08-14 2002-09-11 Univ California FLUORESZIERENDE AMYLOID A beta PEPTIDE UND DEREN VERWENDUNG
JP4537577B2 (ja) * 1998-03-13 2010-09-01 ユニバーシティ・オブ・ワシントン アルツハイマー病及びプリオン病の治療に関する抗プラーク療法を特定するコンゴ好染性マルタ十字形アミロイドプラークのｉｎｖｉｔｒｏにおける形成

Also Published As

Publication number Publication date
NO20023163L (no) 2002-08-27
IL150080A0 (en) 2002-12-01
DE60039310D1 (de) 2008-08-07
EP1242822B1 (de) 2008-06-25
CA2395789C (en) 2010-03-30
AU774377B2 (en) 2004-06-24
AU1810301A (en) 2001-07-16
KR20020070470A (ko) 2002-09-09
NO20023163D0 (no) 2002-06-28
NZ519612A (en) 2004-04-30
HK1046550B (zh) 2008-12-19
EP1242822A2 (de) 2002-09-25
US6399314B1 (en) 2002-06-04
EA005582B1 (ru) 2005-04-28
IL150080A (en) 2009-02-11
MXPA02006362A (es) 2002-11-29
JP2003519383A (ja) 2003-06-17
CN1415074A (zh) 2003-04-30
DK1242822T3 (da) 2008-09-29
BR0016883A (pt) 2002-10-01
PL356813A1 (en) 2004-07-12
EA200200722A1 (ru) 2002-12-26
ES2309003T3 (es) 2008-12-16
HK1046550A1 (en) 2003-01-17
WO2001050134A3 (en) 2002-06-27
PT1242822E (pt) 2008-09-29
CN1211661C (zh) 2005-07-20
CA2395789A1 (en) 2001-07-12
WO2001050134A2 (en) 2001-07-12

Similar Documents

Publication Publication Date Title
DE60039310D1 (de) Verfahren zur bestimmung von amyloidogenen proteinen
ATE538809T1 (de) Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff
DK0679251T3 (da) Fremgangsmåde og apparat til vurdering af biopolymerers fitness
EP1664783A4 (de) Schnelltest für glykiertes albumin
MX2020009278A (es) Ensayos para detectar la neurodegeneración.
ATE494393T1 (de) Testverfahren für nukleinsäuren mittels fluoreszenz
Ehrnhoefer et al. A quantitative method for the specific assessment of caspase-6 activity in cell culture
DE59914830D1 (de) Verfahren und testbesteck zur beurteilung der oxid messung ihrer antiradikalen aktivität
Strucksberg et al. Proteasomal activity in skeletal muscle: a matter of assay design, muscle type, and age
ATE514951T1 (de) Verfahren zur prüfung eines mehrkanaligen elements zur blutanalyse
ATE299589T1 (de) Verfahren zur bestimmung von substanzen mittels der evaneszenzfeldmethode
Zinellu et al. Highly sensitive simultaneous detection of cultured cellular thiols by laser induced fluorescence‐capillary electrophoresis
JPH01210863A (ja) 精子細胞計数および生存精子細胞の比率、あるいは、これらいずれか一方の高速定量方法ならびにその装置
DE50212790D1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
RU2013158623A (ru) Способ идентификации лигандов для белков, агрегированных в бета-листы
DE602005015627D1 (de) Verfahren zur messung von proinsulin und c-peptid sowie kit dafür
ATE466285T1 (de) Diagnose von leberzirrhose mittels eines für menschliches protoonkogenes protein spezifischen antikörpers
DE60324820D1 (de) Verfahren zum testen des oxidiertes-ldl-beta-2-glycoprotein-i-komplexes in vivo
DE69614374D1 (de) Verfahren zur spektralanalyse von inhomogenen proben
DE50213297D1 (de) Verfahren und mittel zur bestimmung von gesamtsäure
ATE317454T1 (de) Verfahren zur aktivitätsbestimmung einer substanz mittels eines funktionellen in vitro tests
RU2315998C2 (ru) Способ определения влияния соединений на процесс скачка митохондриальной проницаемости и мембранный потенциал митохондрий
RU95105705A (ru) Способ определения водонепроницаемости бетона и изделий
JPS55110937A (en) Method of fluometric quantative analysis of amino acid, peptide or protein using sodium n-chloro-1- dimethylaminonaphthalene-5-sulfonamide
WO2002066982A8 (de) Analyse von modifizierungen und demodifizierungen von proteinen mit ubiquintin-verwandten proteinen mittels fret (fluorescence resonance energy transfer)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1242822

Country of ref document: EP

REN Ceased due to non-payment of the annual fee